HIV-1 gag proteins in virions and in infected cell fractions.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

HIV-1 gag proteins in virions and in infected cell fractions.

Biomed Sci. 1991;2(3):279-84. Unique Identifier : AIDSLINE MED/92089500
Sharova NK; Grigor'ev VB; Bukrinskaya AG; D I Ivanovskii Institute of Virology, Academy of Medical Sciences; of the USSR, Moscow.

Abstract: The relation of the initial products of the HIV-1 gag gene to the final products was determined in virus samples and cell fractions of infected H9 and Jurkat-tat cell cultures. The proteins were identified by immunoblotting with pooled sera from AIDS patients or monoclonal antibodies. The proportion in the virions of gag precursor proteins and the products of their proteolytic cleavage varied according to the maturity of the virus particles as determined by electron microscopy. The distribution of viral gag proteins in the cell fractions was determined 2, 4, and 24 h after infection. Treatment of cells with cycloheximide to block de novo protein synthesis did not significantly affect the results. Gag proteins containing the N terminus of the precursor p55 (including p55, the intermediate precursors p41(45) and p39, and mature protein p17) were found in the cell nuclei up to 24 h after infection. The major core protein p24 was located in the cytoplasmic fraction. These data strongly suggest that gag precursors from the p55 N terminus and the matrix protein p17 enter the infected cell separately from the major core protein p24, or become separated from it in the cytoplasm.

Keywords: Acquired Immunodeficiency Syndrome/*METABOLISM Cells, Cultured Gene Products, gag/*ANALYSIS/IMMUNOLOGY Human HIV Antigens/ANALYSIS/IMMUNOLOGY HIV Core Protein p24/CHEMISTRY HIV-1/*CHEMISTRY/GROWTH & DEVELOPMENT/ULTRASTRUCTURE Subcellular Fractions/CHEMISTRY Virion/*CHEMISTRY Virus Replication JOURNAL ARTICLE $KWDchemistry/growth&development/ultrastructuresubcellularfractions/chemistryvirion/$
920430
M9240906

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .